Decades of vigorous endurance training may confer a physiological paradox: the very habits that protect most people from heart disease appear to create distinct cardiovascular vulnerabilities in highly trained older athletes. This joint consensus statement from two of the world's most authoritative cardiology bodies reframes how clinicians should think about cardiac risk in this growing population.
The European Association of Preventive Cardiology, the European Society of Cardiology, and the American College of Cardiology converged on seven clinically significant abnormalities disproportionately observed in Masters athletes — individuals typically defined as competitive exercisers over age 35. These include atrial fibrillation, bradyarrhythmias, ventricular arrhythmias, coronary atherosclerosis, aortic dilatation, myocardial fibrosis, and exercise-induced arrhythmogenic cardiomyopathy. A unifying concern is that existing clinical guidelines for these conditions were largely developed from data on symptomatic, sedentary patients — a population whose physiology diverges substantially from that of a 60-year-old who has logged 40,000 lifetime training miles. The panel also flags consumer wearables as an emerging diagnostic variable, offering continuous cardiac data that may detect subclinical signals outside clinical settings.
This consensus arrives at an important inflection point. Epidemiological research has increasingly documented that the dose-response relationship between exercise and cardiovascular benefit is not strictly linear at lifetime-high volumes. Chronic atrial stretch from sustained high cardiac output, autonomic remodeling, and repetitive myocardial stress are plausible mechanisms behind the elevated arrhythmia burden observed in this cohort. The myocardial fibrosis finding is particularly consequential, as fibrotic remodeling can be arrhythmogenic regardless of underlying athletic capacity. The panel's acknowledgment that Masters athletes may resist pharmacologic intervention adds a behavioral dimension often absent from cardiology guidelines. As a consensus document rather than a randomized trial, the recommendations carry expert-level, not experimental, authority — but the synthesis across seven pathologies in a unified framework represents a meaningful clinical advance for sports cardiologists and internists managing this underserved demographic.